Literature DB >> 30481541

Long noncoding RNA NPCCAT1 promotes nasopharyngeal carcinoma progression via upregulating YY1.

Hongxia Su1, Lei Liu1, Yuan Zhang1, Jia Wang1, Yulin Zhao2.   

Abstract

Long noncoding RNAs (lncRNAs) are frequently implicated in various cancers. However, the significances of lncRNAs in nasopharyngeal carcinoma (NPC) are largely unclear. In this study, we identified a novel lncRNA nasopharyngeal carcinoma copy number amplified transcript-1 (NPCCAT1), whose expression is increased in NPC tissues compared with nasopharyngeal normal tissues. Furthermore, we found the genomic copy number of NPCCAT1 is amplified in NPC, which contributes to the upregulation of NPCCAT1 in NPC. Functional experiments demonstrated that overexpression of NPCCAT1 promotes NPC cell growth and migration in vitro and NPC tumor growth in vivo. Knockdown of NPCCAT1 suppresses NPC cell grow and migration. Mechanistically, we found that NPCCAT1 directly binds YY1 mRNA 5'UTR, promotes YY1 mRNA translation, and upregulates YY1 protein level. Gain-of-function and loss-of-function assays revealed that YY1 promoted NPC cell proliferation and migration. Moreover, rescue assays showed that depletion of YY1 attenuated the roles of NPCCAT1 overexpression in promoting NPC cell growth and migration in vitro and NPC tumor growth in vivo. Overall, our study identified NPCCAT1 as an oncogenic lncRNA which promotes NPC progression via upregulating YY1, and suggested that lncRNA NPCCAT1 may be a promising therapeutic target for NPC.
Copyright © 2018 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Copy number variation; Long noncoding RNA; Nasopharyngeal carcinoma; Progression; YY1

Mesh:

Substances:

Year:  2018        PMID: 30481541     DOI: 10.1016/j.biochi.2018.11.014

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  9 in total

1.  Mechanism of long noncoding RNAs as transcriptional regulators in cancer.

Authors:  Yan Huang; Qi Guo; Xi-Ping Ding; Xiangting Wang
Journal:  RNA Biol       Date:  2020-01-10       Impact factor: 4.652

2.  LINC00667/miR-449b-5p/YY1 axis promotes cell proliferation and migration in colorectal cancer.

Authors:  Juan Yu; Furang Wang; Jun Zhang; Jing Li; Xiaoguang Chen; Guangsen Han
Journal:  Cancer Cell Int       Date:  2020-07-17       Impact factor: 5.722

3.  TMPO-AS1 promotes cell proliferation of thyroid cancer via sponging miR-498 to modulate TMPO.

Authors:  Zhenyu Li; Yun Feng; Zhen Zhang; Xiaozhong Cao; Xiubo Lu
Journal:  Cancer Cell Int       Date:  2020-07-08       Impact factor: 5.722

4.  LINC01116 accelerates nasopharyngeal carcinoma progression based on its enhancement on MYC transcription activity.

Authors:  Haijie Xing; Hongxia Sun; Weiluo Du
Journal:  Cancer Med       Date:  2019-11-08       Impact factor: 4.452

5.  Long non-coding RNA SNHG3 accelerates progression in glioma by modulating miR-384/HDGF axis.

Authors:  Xiaofeng Zhang; Weixin Zheng; Wenting Jiang; Ruisheng Lin; Chunyang Xing
Journal:  Open Life Sci       Date:  2020-09-05       Impact factor: 0.938

6.  Long Noncoding RNA PCED1B-AS1 Promotes the Warburg Effect and Tumorigenesis by Upregulating HIF-1α in Glioblastoma.

Authors:  Zhiqiang Yao; Qiansheng Zhang; Fuyou Guo; Shewei Guo; Bo Yang; Binghui Liu; Panxing Li; Jinyi Li; Sheng Guan; Xianzhi Liu
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 7.  Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.

Authors:  Haihua Wang; Weiyuan Wang; Songqing Fan
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

8.  Long Noncoding RNA UCA1 Accelerates Nasopharyngeal Carcinoma Cell Progression By Modulating miR-124-3p/ITGB1 Axis.

Authors:  Chunxiu Liu; Hu Zhang; Hui Liu
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

Review 9.  The biological implications of Yin Yang 1 in the hallmarks of cancer.

Authors:  Ian Timothy Sembiring Meliala; Rendy Hosea; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.